GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, today highlighted that it is committed to playing a pivotal role in reinforcing ...
EQS-News: GeoVax, Inc. / Key word (s): Financial GeoVax Advanced MVA Manufacturing Process: Aimed to Enhance Vaccine Supply Worldwide 27.01.2025 / 15:04 CET/CEST The issuer is solely responsible ...
GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company specializing in vaccines and immunotherapies, has shared updates about its development-stage advanced Modified Vaccinia Ankara ...
Shares of GeoVax Labs, Inc. (NASDAQ:GOVX – Get Free Report) have been given an average rating of “Buy” by the seven analysts ...
GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company specializing in developing vaccines with a current market ...
D. Boral Capital reissued their buy rating on shares of GeoVax Labs (NASDAQ:GOVX – Free Report) in a research report report published on Thursday,Benzinga reports. The firm currently has a $18.00 ...
Represents a Key Step Toward Validating Gedeptin Potential in Solid Tumor Therapy ATLANTA, GA - January 15, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology ...
MIAMI, Jan. 15, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 78th Emerging Growth Conference on January 15 & 16, 2025.
GeoVax Announces Major Gedeptin Milestone With Plans of Phase 2 Trial 15.01.2025 / 15:05 CET/CEST The issuer is solely responsible for the content of this announcement. Represents a Key Step Toward ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
GeoVax Achieves Significant Progress in Next-Generation COVID-19 Vaccine Development Throughout 2024
Completion of Enrollment in Booster Vaccine Study for Healthy Adult Volunteers GeoVax has successfully completed enrollment in its Phase 2 clinical trial evaluating GEO-CM04S1 as a booster vaccine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback